RNAZ / TransCode Therapeutics, Inc. (RNAZ) CEO Michael Dudley on Q4 2021 Results - Earnings Call Transcript

TransCode Therapeutics (NASDAQ: RNAZ ) stock is taking a beating on Friday after the oncology company announced plans for a public share offering. Tr more_horizontal

TransCode Therapeutics (NASDAQ: RNAZ ) stock is falling hard on Tuesday after the medical company announced a public share offering. According to a p more_horizontal

TransCode Therapeutics (NASDAQ:RNAZ) stock has seen a wild 24 hours of trading as the Boston headquartered nano-cap drug discovery firm rocketed Monda more_horizontal

TransCode Therapeutics (NASDAQ:RNAZ) shares took off after it announced positive results from a study of its lead drug candidate TTX-MC138 in mice mod more_horizontal

TransCode Therapeutics Inc. (RNAZ) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In a more_horizontal

The stock price of TransCode Therapeutics, Inc. (Nasdaq: RNAZ) increased by 4.96% this past week. This is why. more_horizontal

TransCode Therapeutics (NASDAQ: RNAZ ) stock is rocketing higher on Wednesday following positive study results. The big news here has to do with TTX-R more_horizontal

TransCode Therapeutics (NASDAQ: RNAZ ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering. According to t more_horizontal